These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 22843515

  • 1. Active immunotherapy: current state of the art in vaccine approaches for NHL.
    Palomba ML.
    Curr Oncol Rep; 2012 Oct; 14(5):433-40. PubMed ID: 22843515
    [Abstract] [Full Text] [Related]

  • 2. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
    Park HJ, Neelapu SS.
    Br J Haematol; 2008 Jun; 142(2):179-91. PubMed ID: 18422783
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM.
    Adv Pharmacol; 2004 Jun; 51():271-93. PubMed ID: 15464914
    [No Abstract] [Full Text] [Related]

  • 4. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 5. New strategies for vaccination and imunomodulation in NHL.
    Stevenson FK, Zhu D, Rice J.
    Ann Hematol; 2001 Jun; 80 Suppl 3():B132-4. PubMed ID: 11757697
    [Abstract] [Full Text] [Related]

  • 6. Vaccination strategies in the treatment of lymphomas.
    Veelken H, Osterroth F.
    Oncology; 2002 Jun; 62(3):187-200. PubMed ID: 12065865
    [Abstract] [Full Text] [Related]

  • 7. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
    Reinis M.
    Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
    [Abstract] [Full Text] [Related]

  • 8. Vaccination strategies in follicular lymphoma.
    Kannan S, Neelapu SS.
    Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R.
    J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014
    [Abstract] [Full Text] [Related]

  • 10. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
    Ashour AK, Petersen JL, McIlhaney MM, Vose JM, Solheim JC.
    Hybridoma (Larchmt); 2006 Oct 01; 25(5):306-8. PubMed ID: 17044787
    [Abstract] [Full Text] [Related]

  • 11. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R, Levy R.
    Blood Rev; 2009 May 01; 23(3):137-42. PubMed ID: 18951668
    [Abstract] [Full Text] [Related]

  • 12. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
    Caspar CB, Levy S, Levy R.
    Blood; 1997 Nov 01; 90(9):3699-706. PubMed ID: 9345055
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.
    Cancer Res; 2002 Oct 15; 62(20):5845-52. PubMed ID: 12384547
    [Abstract] [Full Text] [Related]

  • 14. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
    Hurvitz SA, Timmerman JM.
    Curr Opin Oncol; 2005 Sep 15; 17(5):432-40. PubMed ID: 16093791
    [Abstract] [Full Text] [Related]

  • 15. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.
    Muraro E, Martorelli D, Dolcetti R.
    Hum Vaccin Immunother; 2013 May 15; 9(5):1078-83. PubMed ID: 23406835
    [Abstract] [Full Text] [Related]

  • 16. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
    Koumarianou A, Kountourakis P, Economopoulos T.
    J Steroid Biochem Mol Biol; 2008 Apr 15; 109(3-5):230-2. PubMed ID: 18406604
    [Abstract] [Full Text] [Related]

  • 17. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
    Leitch HA, Connors JM.
    Curr Opin Investig Drugs; 2005 Jun 15; 6(6):597-604. PubMed ID: 15988911
    [Abstract] [Full Text] [Related]

  • 18. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA, Neelapu SS, Kwak LW, Biragyn A.
    Haematologica; 2002 Sep 15; 87(9):989-1001. PubMed ID: 12217812
    [Abstract] [Full Text] [Related]

  • 19. Idiotype vaccine strategies for treatment of follicular lymphoma.
    Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR.
    Future Oncol; 2011 Jan 15; 7(1):111-22. PubMed ID: 21174542
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H.
    Cancer Res; 2006 Apr 15; 66(8):4496-502. PubMed ID: 16618777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.